key: cord-1000002-v6vly97n
authors: Suzuki, Y.; Shibata, Y.; Minemura, H.; Nikaido, T.; Tanino, Y.; Fukuhara, A.; Kanno, R.; Saito, H.; Suzuki, S.; Ishii, T.; Inokoshi, Y.; Sando, E.; Sakuma, H.; Kobayashi, T.; Kume, H.; Kamimoto, M.; Aoki, H.; Takama, A.; Kamiyama, T.; Nakayama, M.; Saito, K.; Tanigawa, K.; Sato, M.; Kanbe, T.; Kanzaki, N.; Azuma, T.; Sakamoto, K.; Nakamura, Y.; Otani, H.; Waragai, M.; Maeda, S.; Ishida, T.; Sugino, K.; Tsukada, Y.; Yamada, R.; Sato, R.; Omuna, T.; Tomita, H.; Saito, M.; Watanabe, N.; Rikimaru, M.; Kawamata, T.; Umeda, T.; Morimoto, J.; Togawa, R.; Sato, Y.; Saito, J.; Kanazawa, K.; Iseki, K.
title: Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic
date: 2021-12-21
journal: nan
DOI: 10.1101/2021.12.19.21268078
sha: 80a76ec65956795f6ebfc33dab70f7cc8fade308
doc_id: 1000002
cord_uid: v6vly97n

Background: Mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may reduce the efficacy of neutralizing monoclonal antibody therapy against coronavirus disease 2019 (COVID-19). We here evaluated the efficacy of casirivimab-imdevimab in patients with mild-to-moderate COVID-19 during the Delta variant surge in Fukushima Prefecture, Japan. Methods: We enrolled 949 patients with mild-to-moderate COVID-19 who were admitted to hospital between July 24, 2021 and September 30, 2021. Clinical deterioration after admission was compared between casirivimab-imdevimab users (n = 314) and non-users (n = 635). Results: The casirivimab-imdevimab users were older (P < 0.0001), had higher body temperature ([≥] 38 degree) (P < 0.0001) and greater rates of history of cigarette smoking (P = 0.0068), hypertension (P = 0.0004), obesity (P < 0.0001), and dyslipidemia (P < 0.0001) than the non-users. Multivariate logistic regression analysis demonstrated that receiving casirivimab-imdevimab was an independent factor for preventing deterioration (odds ratio 0.448; 95% confidence interval 0.263 to 0.763; P = 0.0023). Furthermore, in 222 patients who were selected from each group after matching on the propensity score, deterioration was significantly lower among those receiving casirivimab-imdevimab compared to those not receiving casirivimab-imdevimab (7.66% vs 14.0%; p = 0.021). Conclusion: This real-world study demonstrates that casirivimab-imdevimab contributes to the prevention of deterioration in COVID-19 patients after hospitalization during a Delta variant surge.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101/2021.12.19.21268078 doi: medRxiv preprint 8 casirivimab-imdevimab compared to those not receiving casirivimab-imdevimab (7.66% vs 14.0%; p = 0.021).

Conclusion: This real-world study demonstrates that casirivimab-imdevimab contributes to the prevention of deterioration in COVID-19 patients after hospitalization during a Delta variant surge. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101/2021.12.19.21268078 doi: medRxiv preprint 9 LDH: lactate dehydrogenase OR: odds ratio PCR: polymerase chain reaction SARS-CoV-2: severe acute respiratory syndrome coronavirus 2 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101/2021.12.19.21268078 doi: medRxiv preprint

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is continuing to spread around the world.

Vaccines against SARS-CoV-2 have reduced infection and mortality and being widespread all over the world. Newly emerging variants have mutations in the spike protein of SARS-CoV-2 and show high infectivity [1] . Many neutralizing antibodies and vaccines against SARS-CoV-2 target this spike protein. Therefore, spike protein mutations may diminish their effectiveness [2] . Indeed, cases of the B.1.617.2 (Delta) variant, which possesses high transmissibility, spread throughout Japan from July to October 2021 [3] .

Neutralizing monoclonal antibody therapy has been authorized by the United States Food and Drug Administration for treatment of high-risk patients with mild-tomoderate COVID-19 [4, 5] . Casirivimab-imdevimab is two recombinant human IgG1 monoclonal antibodies, known as REGN-COV2, that are used for the treatment of COVID-19 [5] . These antibodies are derived from humanized mice and the sera of patients recovering from COVID-19, and bind non-competitively to non-overlapping epitopes of the spike protein receptor-binding domain of SARS-CoV-2, thereby preventing viral attachment and cell entry [6, 7] . To date, a few investigations have All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in reported the real-world effect of casirivimab-imdevimab as outpatient treatment for mild-to-moderate COVID-19 cases with high-risk aggravations [8] [9] [10] . These studies demonstrated that use of casirivimab-imdevimab decreased hospitalization and mortality rates. However, it remains unclear whether casirivimab-imdevimab is also effective for treatment of the SARS-CoV-2 Delta variant.

Starting in March 2020, we have been gathering the medical information of patients with COVID-19, who were hospitalized in 26 medical institutes in Fukushima Prefecture, in our electronic database. A total of 4,568 COVID-19 patients were registered by the end of September 2021. Even in Fukushima Prefecture, the Delta variant was widely spread, and from July to September 2021, the most frequently detected variant of SARS-CoV-2 was the Delta variant [11] . Furthermore, starting in July 2021, casirivimab-imdevimab has been approved in Japan for treating mild-tomoderate COVID-19 patients who are at high-risk of deterioration. Hence, our database was available to evaluate the clinical efficacy of casirivimab-imdevimab against SARS-CoV-2 in the real-world setting.

To the best of our knowledge, the present study is the first real-world retrospective study to evaluate the efficacy of casirivimab-imdevimab for cases of mildto-moderate COVID-19 caused by the Delta variant of SARS-CoV-2. We compared the All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101/2021.12.19.21268078 doi: medRxiv preprint clinical outcomes of patients with mild-to-moderate COVID-19 treated with casirivimabimdevimab therapy to those who underwent alternative treatments.

This retrospective cohort study was conducted using an electronic database and enrolled 4,568 COVID-19 patients (as of the end of September 2021) who were admitted to 26 hospitals in Fukushima Prefecture. Those hospitals participated in the web conferences organized by the Department of Pulmonary Medicine, Fukushima Medical University. Among the 4,568 patients, the data of 790 were excluded, because those patients had severe COVID-19, treatment for which casirivimab-imdevimab is not eligible. Among the remaining 3,778 patients, we excluded 2,829 as they were admitted before casirivimab-imdevimab became available on July 24, 2021 in Fukushima prefecture. Finally, we analyzed the data of 949 patients. The subjects in the current study included patients who had been vaccinated against SARS-CoV-2.

The clinical characteristics, including comorbidities, examination results, medications, as well as clinical course and outcomes of the subjects, were obtained from the electronic database of each hospital. In the current study, the subjects who received All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Retrospectively, the patients were divided into two groups: (1) those treated with casirivimab-imdevimab; and (2) those not treated with casirivimab-imdevimab (controls). If a patient's condition deteriorated during the clinical course after the administration of casirivimab-imdevimab, other therapies for COVID-19, including antiviral drugs or immunomodulatory agents (remdesivir, favipiravir, corticosteroid, baricitinib, or tocilizumab), were prescribed and administered at the attending doctor's discretion.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

The inclusion criteria for treatment with casirivimab-imdevimab were guided by those for the COV-2067 trial [5] , and the recommendation of the Japanese Ministry of Health, Labor and Welfare [12] . In particular, patients who were aged ≥ 18 years were eligible for casirivimab-imdevimab treatment if they had symptoms of COVID-19 (e.g., cough, sore throat, fever, and constitutional symptoms), were within 7 days of symptom onset, and had at least one of the following criteria for high risk aggravation: an age of ≥ 50 years, body mass index (BMI) of ≥ 30 kg/m 2, use of immunosuppressive medication, immunocompromised status, and presence of hypertension, cardiovascular disease, chronic lung disease, chronic kidney disease (CKD), diabetes mellitus and/or chronic liver disease.

The primary outcomes of interest were any clinical deterioration, need for mechanical ventilation/ECMO, and death after initiation of casirivimab-imdevimab. The secondary outcomes included factors that influenced clinical deterioration.

The definition of clinical deterioration in the present study was a worsened respiratory condition requiring respiratory therapy (use of inhalation oxygen, All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101/2021.12.19.21268078 doi: medRxiv preprint mechanical ventilation, or ECMO) or the initiation of other medications for COVID-19 (remdesivir, favipiravir, corticosteroid, baricitinib, or tocilizumab) after the first day of hospitalization.

Continuous variables are shown as median with interquartile range (IQR) and categorical variables are shown as numbers and percentages. Comparisons between groups for the continuous variables and categorical variables were performed using Mann-Whitney U test and chi-square test, respectively. Age was reclassified as a categorical variable according to the cutoff values obtained from the receiver operating characteristic (ROC) curve of univariate logistic regression analysis for predicting deterioration during hospitalization. Based on the ROC curve and Youden index analysis, we determined that the best cut-off age was 43 (sensitivity 73.6%, specificity 56.4%). Among the comorbidities, those with a prevalence of ≥ 2% were applied to the analyses. The variables that had statistically significant differences between the casirivimab-imdevimab users and non-users were used to identify independent risk factors for predicting deterioration a day or later after admission via multivariate logistic regression analysis. Adjusted odds ratios (OR) with 95% confidence interval (CI) were All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101/2021.12.19.21268078 doi: medRxiv preprint calculated.

In addition, we compared the risk of exacerbation between the casirivimabimdevimab users and non-users using the DOAT score. The DOAT score is a simple predictive model that we established and reported in a previous study [14] . It consists of three items: 1) having the comorbidity of diabetes or obesity, 2) being aged ≥ 40 years, and 3) having high body temperature (≥ 38°C). The DOAT score range is 0-3 points, and a high DOAT score (optimal cutoff point is 2) denotes a higher possibility of deterioration in non-elderly COVID-19 patients who do not have respiratory failure on admission.

Furthermore, we used the propensity score technique to match casirivimabimdevimab users and non-users. The propensity score method selected covariates that may influence casirivimab-imdevimab administration [15] . Logistic regression was performed to estimate the propensity of initiating casirivimab-imdevimab users versus non-user, including 14 confounders that are related to deterioration risk (age, sex, cigarette smoking, high body temperature, percutaneous oxygen saturation, severity, receiving the vaccine, hypertension, obesity, diabetes, dyslipidemia, respiratory diseases, CKD, and collagen vascular disease). We then matched subjects on the logit of the propensity score using a caliper of width equal to 0.2 of the standard deviation All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101/2021.12.19.21268078 doi: medRxiv preprint of logit of the propensity score [16] . We excluded patients with moderate-2 and severe status from the analyses, because we were unable to match them with control patients.

All statistical analyses were performed using JMP 13 (SAS Institute Inc, Cary NC) and EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan). A two-tailed p-value of < 0.05 was considered statistically significant. Cases with missing data were not excluded from the analyses.

The need for informed consent was waived because the study is retrospective.

This study was approved by the Ethics Committee of Fukushima Medical University (approval number 2020-118, approved on August 3, 2020, updated September 01, 2021).

The patient selection flowchart is shown in Figure 1 . Among the 949 COVID-19 patients enrolled in the current study, 314 were administered casirivimabimdevimab. The differences in characteristics between the casirivimab-imdevimab All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101/2021.12.19.21268078 doi: medRxiv preprint users and non-users are demonstrated in Table 1 . The casirivimab-imdevimab users were significantly older (P < 0.0001), and had higher body temperature (≥ 38°C) (P < 0.0001) and a higher history of cigarette smoking (P = 0.0068) compared to the nonusers. The disease severity was significantly higher in the non-users compared to the casirivimab-imdevimab users (P = 0.0003). Regarding comorbidities, in the casirivimab-imdevimab users, there was a significantly higher prevalence of hypertension (P = 0.0004), obesity (P < 0.0001), and dyslipidemia (P < 0.0001). There were no significant differences in sex, diabetes, chronic respiratory diseases, malignancies, cardiac disease, CKD, and being vaccinated between the two groups.

With regard to physical and laboratory examinations, ferritin levels (P = 0.0102) and

DOAT score (P < 0.0001) were significantly higher in the casirivimab-imdevimab users than in the non-users. On the other hand, percutaneous oxygen saturation level, white blood cells, neutrophil percentage, lymphocyte percentage, C-reactive protein (CRP), lactate dehydrogenase (LDH), and D-dimer did not significantly differ between the groups.

Among all patients analyzed in the present study, 104 experienced All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101/2021.12.19.21268078 doi: medRxiv preprint deterioration a day after admission or later. The primary endpoints of the rates of clinical deterioration, need for mechanical ventilation/ECMO, and death for the total population were 11.0%, 0.53%, and 0.63%, respectively. One casirivimab-imdevimab user with moderate-1 status died, and there were no significant differences regarding rates of clinical deterioration, need for mechanical ventilation/ECMO and death between the two groups ( Table 2 ).

The results of multivariate logistic regression analysis of COVID-19 deterioration during hospitalization are shown in Table 3 . According to this analysis, age ≥ 43 years (P = 0.0004), being unvaccinated (P = 0.0002), not receiving casirivimab-imdevimab (P = 0.0023), and dyslipidemia (P = 0.0290) were independent risk factors related to the clinical deterioration of COVID-19 (Table 3) .

Using the propensity score matching method, 222 patients were selected from each group. The baseline clinical characteristics after adjusting for propensity score All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Table 4 . There were no significant differences between the two groups, except for the percentage of neutrophils in blood test. The clinical deterioration rate was significantly lower in the casirivimab-imdevimab users compared to the nonusers (7.66% vs 14.0%; p = 0.021). None of the 222 patients in both groups required mechanical ventilation/ECMO. One casirivimab-imdevimab user died, but there was no significant difference regarding the death rate between the two groups ( Table 5 ).

In the present study, we investigated the effectiveness of casirivimabimdevimab utilizing real-world data from 949 COVID-19 patients who had been admitted to hospitals in Fukushima Prefecture between July 2021 and September 2021 during the Delta variant pandemic. The patients taking casirivimab-imdevimab were older and had more frequent comorbidities such as hypertension, obesity, and dyslipidemia compared to those who were not taking casirivimab-imdevimab. These differences may have been caused by the eligibility criteria of treatment with casirivimab-imdevimab. Thus, it is natural that the DOAT score [14] , which is a predictive score of disease progression in COVID-19 patients with mild-to-moderate-1 severity, was higher in the casirivimab-imdevimab users than in the non-users. On the All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101/2021.12.19.21268078 doi: medRxiv preprint other hand, the disease severity was significantly higher in the non-users. There was no significant difference in clinical outcomes between the two groups in the analysis of data before adjustment for differences in patient characteristics. However, because there were several significant differences in clinical characteristics between the two groups, we performed a multivariate logistic regression analysis that included the confounding factors as explanatory variables. The analysis results demonstrated that not receiving casirivimab-imdevimab was an independent risk factor for deterioration of COVID-19. Furthermore, a propensity score matching analysis for mild-to-moderate patients revealed the effectiveness of casirivimab-imdevimab hidden behind the confounding factors. These results are consistent with a previous study that showed casirivimab-imdevimab treatment to be associated with a significantly lower rate of hospitalization among high-risk patients with mild-to-moderate COVID-19 [9] .

In the current study, information on SARS-CoV-2 variants in individual cases was unknown. However, according to a survey performed by the Fukushima Prefectural Institute of Public Health, the proportion of Delta variant cases reached 70% by the end of July 2021 in Fukushima Prefecture, and exceeded 90% after the middle of the following month [11] . Therefore, it is reasonable to consider that almost all cases analyzed in the present study were Delta variant cases. Thus, the results of All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The Delta variant, which was first detected in India in 2020, has attained global dominance with a higher transmissibility and immune evasion [17] . In vitro and in vivo, perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101/2021.12.19.21268078 doi: medRxiv preprint believe that casirivimab-imdevimab is suggested to be effective for the treatment of the SARS-CoV-2 Delta variant.

The efficacy of SARS-CoV-2 vaccine against the Delta variant was also revealed by multivariate logistic regression analysis in the present study (Table 3) The strength of the current study is that its results are considered to be generalizable because the population was comprised of inpatients at major hospitals in Fukushima Prefecture that handle COVID-19 inpatient treatment. During the study All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in There are several limitations to the present study. First, this was an observational and retrospective study, and does not show evidence comparable to a randomized clinical trial. Although we carefully adjusted clinical outcomes for various potential cofounding factors, potential bias due to the study design is inevitable.

Second, in some subjects, the precise information about the number of days between COVID-19 symptom onset and the administration of casirivimab-imdevimab, and the day of deterioration were not included in our electronic database. Therefore, there may be some influence on the clinical outcomes. Third, the adverse effects of casirivimabimdevimab were not evaluated in detail. However, according to previous studies, adverse effects were uncommon and mild [5, 10] . Fourth, information regarding which SARS-CoV-2 variant each individual had was not included in the current study.

However, as we mentioned above, almost all patients were considered to be infected with the Delta variant during the study period in most of Japan [3] , including Fukushima Prefecture [11] . Fifth, regarding the vaccinated patients information on how many days before disease onset they completed SARS-CoV-2 vaccination was not available. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in (Table 3) . Sixth, as the study population was almost entirely Japanese, different results may be obtained with different ethnic population. Further study is needed to validate these findings in other ethnic populations.

This real-world retrospective study of high-risk patients with mild-to-moderate COVID-19 demonstrated a low rate of clinical deterioration after treatment with casirivimab-imdevimab, regardless of whether the patients had received a SARS-CoV-2 vaccine. Aggressive use of casirivimab-imdevimab should be considered to prevent deterioration in high-risk patients with mild-to-moderate COVID-19.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in COVID-19 severity grade: mild, subjects without pneumonia or respiratory failure; moderate-1, subjects with pneumonia but without having respiratory failure; moderate-2, subjects with pneumonia and respiratory failure (oxygen saturation < 94% on room air) but who do not require mechanical ventilation/extracorporeal membrane oxygenation (ECMO); and severe, subjects with pneumonia and respiratory failure who require mechanical ventilation/ECMO Definition of abbreviations: CI, confidence interval; OR, odds ratio. Definition of abbreviations: CRP, C-reactive protein; LDH, lactate dehydrogenase; SpO2, percutaneous oxygen saturation. 

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies

Predicted dominance of variant Delta of SARS-CoV-2 before

Euro surveillance : bulletin Europeen sur les maladies transmissibles =

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

All rights reserved. No reuse allowed without permission. perpetuity

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

Neutralizing monoclonal antibodies for treatment of COVID-19

Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease

Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19

Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate COVID-19: A Real-World Experience

Clinical Management of patients with COVID-19: A guide for front-line healthcare workers

Evaluation of Biomarkers of Severity in Patients with COVID-19 Infection

Development and external validation of the DOAT and DOATS scores: simple decision support tools to identify disease progression among nonelderly patients with mild/moderate COVID-19. medRxiv

Using Propensity Scores for Causal Inference: Pitfalls and Tips

Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

All rights reserved. No reuse allowed without permission. perpetuity

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted

SpO2, % 97 (96, 98) 97 (96, 98) 97 (96

White blood cells

We thank the Scientific English Editing Section of Fukushima Medical University for their fruitful discussion and linguistic assistance in proofreading the manuscript. were selected for the present study.